Compile Data Set for Download or QSAR
Report error Found 220 Enz. Inhib. hit(s) with all data for entry = 8749
TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416465(US10301261, Compound BE-19.1 | N-(4-(ethylsulfonyl...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416465(US10301261, Compound BE-19.1 | N-(4-(ethylsulfonyl...)
Affinity DataIC50: 100nMAssay Description:Compounds described herein were tested for RORγ inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanoluc lucif...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416466(US10301261, Compound BE-19.2 | N-(4-(ethylsulfonyl...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416463(US10301261, Compound BE-18.1 | 1-cyclopropyl-N-(4-...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416463(US10301261, Compound BE-18.1 | 1-cyclopropyl-N-(4-...)
Affinity DataIC50: 100nMAssay Description:Compounds described herein were tested for RORγ inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanoluc lucif...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416463(US10301261, Compound BE-18.1 | 1-cyclopropyl-N-(4-...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416461(US10301261, Compound BE-16 | (R)-1-cyclopropyl-2-(...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416461(US10301261, Compound BE-16 | (R)-1-cyclopropyl-2-(...)
Affinity DataIC50: 100nMAssay Description:Compounds described herein were tested for RORγ inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanoluc lucif...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416462(US10301261, Compound BE-17 | (R)-2-(cyclopropylmet...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416459(US10301261, Compound BE-14 | (R)-1-ethyl-N-(1-(4-(...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416459(US10301261, Compound BE-14 | (R)-1-ethyl-N-(1-(4-(...)
Affinity DataIC50: 100nMAssay Description:Compounds described herein were tested for RORγ inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanoluc lucif...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416460(US10301261, Compound BE-15 | (R)-1-cyclopropyl-N-(...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416460(US10301261, Compound BE-15 | (R)-1-cyclopropyl-N-(...)
Affinity DataIC50: 100nMAssay Description:Compounds described herein were tested for RORγ inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanoluc lucif...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416474(US10301261, Compound BE-26.2 | N-((5-(ethylsulfony...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416475(US10301261, Compound BE-27.1 | US10301261, Compoun...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416472(US10301261, Compound BE-25 | 1-cyclopropyl-N-((S)-...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416472(US10301261, Compound BE-25 | 1-cyclopropyl-N-((S)-...)
Affinity DataIC50: 100nMAssay Description:Compounds described herein were tested for RORγ inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanoluc lucif...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416473(US10301261, Compound BE-26.1 | N-((5-(ethylsulfony...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416469(US10301261, Compound BE-22 | 1-cyclopropyl-N-((S)-...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416470(US10301261, Compound BE-23 | 1-ethyl-N-((R)-1-(4-(...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416470(US10301261, Compound BE-23 | 1-ethyl-N-((R)-1-(4-(...)
Affinity DataIC50: 100nMAssay Description:Compounds described herein were tested for RORγ inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanoluc lucif...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416467(US10301261, Compound BE-20 | 1-ethyl-N-(4-(ethylsu...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416467(US10301261, Compound BE-20 | 1-ethyl-N-(4-(ethylsu...)
Affinity DataIC50: 100nMAssay Description:Compounds described herein were tested for RORγ inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanoluc lucif...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416468(US10301261, Compound BE-21 | 1-cyclopropyl-N-((R)-...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416468(US10301261, Compound BE-21 | 1-cyclopropyl-N-((R)-...)
Affinity DataIC50: 100nMAssay Description:Compounds described herein were tested for RORγ inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanoluc lucif...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416482(US10301261, Compound BE-33 | 1-cyclopropyl-N-(4-(N...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416482(US10301261, Compound BE-33 | 1-cyclopropyl-N-(4-(N...)
Affinity DataIC50: 100nMAssay Description:Compounds described herein were tested for RORγ inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanoluc lucif...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416480(US10301261, Compound BE-31 | 1-cyclopropyl-N-((5-(...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416481(US10301261, Compound BE-32 | 1-cyclopropyl-N-((R)-...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416481(US10301261, Compound BE-32 | 1-cyclopropyl-N-((R)-...)
Affinity DataIC50: 100nMAssay Description:Compounds described herein were tested for RORγ inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanoluc lucif...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416477(US10301261, Compound BE-28 | 1-cyclopropyl-N-((R)-...)
Affinity DataIC50: 100nMAssay Description:Compounds described herein were tested for RORγ inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanoluc lucif...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416479(US10301261, Compound BE-30 | 1-cyclopropyl-N-(4-(m...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416479(US10301261, Compound BE-30 | 1-cyclopropyl-N-(4-(m...)
Affinity DataIC50: 100nMAssay Description:Compounds described herein were tested for RORγ inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanoluc lucif...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416475(US10301261, Compound BE-27.1 | US10301261, Compoun...)
Affinity DataIC50: 100nMAssay Description:Compounds described herein were tested for RORγ inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanoluc lucif...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416475(US10301261, Compound BE-27.1 | US10301261, Compoun...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416477(US10301261, Compound BE-28 | 1-cyclopropyl-N-((R)-...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416492(US10301261, Compound BE-43 | N-((5-(ethylsulfonyl)...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416488(US10301261, Compound BE-39 | N-(4-(ethylsulfonyl)b...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416490(US10301261, Compound BE-41 | N-(4-(ethylsulfonyl)b...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416486(US10301261, Compound BE-37 | N-(4-(ethylsulfonyl)b...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416486(US10301261, Compound BE-37 | N-(4-(ethylsulfonyl)b...)
Affinity DataIC50: 100nMAssay Description:Compounds described herein were tested for RORγ inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanoluc lucif...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416487(US10301261, Compound BE-38 | 1-cyclobutyl-N-(4-(et...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416484(US10301261, Compound BE-35 | 1-ethyl-N-(4-(ethylsu...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416484(US10301261, Compound BE-35 | 1-ethyl-N-(4-(ethylsu...)
Affinity DataIC50: 100nMAssay Description:Compounds described herein were tested for RORγ inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanoluc lucif...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416485(US10301261, Compound BE-36 | 1-cyclopropyl-N-(4-(e...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416485(US10301261, Compound BE-36 | 1-cyclopropyl-N-(4-(e...)
Affinity DataIC50: 100nMAssay Description:Compounds described herein were tested for RORγ inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanoluc lucif...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416497(US10301261, Compound BE-47 | (R)-1-cyclopropyl-N-(...)
Affinity DataIC50: 100nMAssay Description:Compounds described herein were tested for RORγ inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanoluc lucif...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416498(US10301261, Compound BE-48 | 1-cyclopropyl-2-(4-(d...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416498(US10301261, Compound BE-48 | 1-cyclopropyl-2-(4-(d...)
Affinity DataIC50: 100nMAssay Description:Compounds described herein were tested for RORγ inverse agonist activity in a cell-based, transcriptional activity assay. Secreted Nanoluc lucif...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM416499(US10301261, Compound BE-49 | tert-butyl 4-((1-cycl...)
Affinity DataKi: <100nMAssay Description:Compounds described herein were tested for ability to bind to RORγ in a cell-free competition assay with commercially available radio-ligand (RL...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

Displayed 1 to 50 (of 220 total ) | Next | Last >>
Jump to: